Key result
Current clinical evidence for repurposing aspirin in COVID-19 remains premature and contradictory, with the only large RCT showing no significant reduction in 28-day mortality.
Why the study?
Severe COVID-19 causes life-threatening thromboembolic complications and hyperinflammation, but evidence supporting the use of repurposed aspirin remains fragile and premature.
Does aspirin reduce mortality and disease severity in patients with COVID-19?
Does aspirin reduce mortality and disease severity in patients with COVID-19?
Despite theoretical anti-inflammatory and antithrombotic benefits, current clinical evidence is conflicting and insufficient to routinely recommend aspirin for the treatment of COVID-19.
Insufficient evidence precludes routine aspirin use in COVID-19; leaves open whether targeted RCTs can resolve contradictory findings.
Since its emergence, the COVID-19 pandemic has been ravaging the medical and economic sectors even with the significant vaccination advances. In severe presentations, the disease of SARS-CoV-2 can manifest with life-threatening thromboembolic and multi-organ repercussions provoking notable morbidity and mortality. The pathogenesis of such burdensome forms has been under extensive investigation and is attributed to a state of immune dysfunction and hyperinflammation. In light of these extraordinary circumstances, research efforts have focused on investigating and repurposing previously available agents that target the inflammatory and hematological cascades. Aspirin, due to its well-known properties and multiple molecular targets, and ought to its extensive clinical use, has been perceived as a potential therapeutic agent for COVID-19. Aspirin acts at multiple cellular targets to achieve its anti-inflammatory and anti-platelet effects. Although initial promising clinical data describing aspirin role in COVID-19 has appeared, evidence supporting its use remains fragile and premature. This review explores the notion of repurposing aspirin in COVID-19 infection. It delves into aspirin as a molecule, along with its pharmacology and clinical applications. It also reviews the current high-quality clinical evidence highlighting the role of aspirin in SARS-CoV-2 infection.
No takes yet. Share an insight, caveat, or question.
Zareef et al. (2022) conducted a review in COVID-19. Aspirin was evaluated. Current clinical evidence for repurposing aspirin in COVID-19 remains premature and contradictory, with the only large RCT showing no significant reduction in 28-day mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: